[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580116":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":30,"locations":39,"responsibleParty":55,"collaborators":21,"id":57,"slug":21,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":21,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":21,"enrollmentInfo":65,"targetDuration":21,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":77,"whyStopped":21,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"The Affiliated Hospital Of Guizhou Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"treatment group","EXPERIMENTAL","The subjects were treated with adalimumab (HS016) in combination with secukinumab",[13,14],"Drug: Secukinumab","Drug: Adalimumab",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Secukinumab","The subjects were treated with secukinumab for 104 weeks. Secukinumab:150mg，q8w，subcutaneous injection.",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Adalimumab","The subjects were treated with adalimumab for 104 weeks. adalimumab: 40mg，q4w，subcutaneous injection.",[9],[27],{"name":28,"affiliation":5,"role":29},"Jiashun Zeng, Medical Doctor","PRINCIPAL_INVESTIGATOR",[31,35],{"name":28,"role":32,"phone":33,"phoneExt":21,"email":34},"CONTACT","13984846802","zengjiashun@sina.com",{"name":36,"role":32,"phone":37,"phoneExt":21,"email":38},"Pengjia Wu, Master","15085969933","1015066791@qq.com",[40],{"facility":41,"status":21,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"The Affiliated Hospital of Guizhou Medical University","Guiyang","Guizhou","550002","China",{"type":47,"coordinates":48},"Point",[49,50],106.71667,26.58333,{"lat":50,"lon":49},[53],{"name":54,"role":32,"phone":33,"phoneExt":21,"email":34},"Jiashun Zeng, Doctor",{"type":56,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100580116",false,"NCT06833112","Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis","Efficacy and Safety of Interleukin-17 Inhibitor in Combination With Tumor Necrosis Factor α Inhibitor in the Treatment of Ankylosing Spondylitis","Inclusion Criteria:\n\n1. Male or female at least 18 years old;\n2. diagnosed with AS according to the 1984 New York Modified Criteria;\n3. Poor response after at least 2 NSAIDs (cumulative treatment ≥ 4 weeks), or contraindication or intolerance to NSAIDs therapy;\n4. BASDAI score of ≥ 4 and total back pain VAS score of ≥ 4 at baseline;\n5. Subjects who need to take NSAIDs (including COX-1 or COX-2 inhibitors) as established treatment for AS, and the NSAIDs should be on a stable dose for at least 2 weeks (inclusive) before screening and the dose is expected to be stable during the study;\n6. Voluntary treatment with adalimumab and secukinumab;\n7. Appropriate contraceptive measures for women of childbearing age;\n8. without other rheumatic diseases.\n9. Able to understand study requirements, provide written informed consent, and comply with trial protocol procedures (including required visits)\n\nExclusion Criteria:\n\n1. With unstable vital signs, coma, mental and cognitive impairment;\n2. Patients with severe systemic diseases and other serious chronic diseases;\n3. Pregnant or lactating patients;\n4. History of malignant tumor in the past 5 years;\n5. Positive test for the following infection markers: human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis antibody;\n6. Patients with active or recurrent history of infection; With active tuberculosis or have a history of active tuberculosis in the past;\n7. Moderate to severe heart failure (New York Heart Association grade 3-4);\n8. Allergic to any of the components of adalimumab (HS016) or secukinumab;\n9. Subjects who are participating in clinical research of other drugs;\n10. In addition to the above, the investigator judged that there are other reasons that are not suitable for participating in this clinical study.","ALL","18 Years",{"count":66,"type":67},10,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","The aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis.",[73],"Ankylosing Spondylitis",[75,18,76],"ankylosing spondylitis","adalimumab","NOT_YET_RECRUITING","2025-02-15",{"date":80,"type":81},"2025-02-18","ACTUAL",{"date":83,"type":67},"2025-02",{"date":85,"type":67},"2028-02",{"name":5,"class":6},1]